“Johnson & Johnson and Leiden University are partners, both located at the Leiden Bio Science Park (LBSP), so we are pleased to make this land available,” said Joek Kruiderink, project director for Area Development at Leiden University Real Estate. “Collaboration with companies at LBSP is important for the university. We focus on supporting the growth of established companies, as this can enhance our partnerships.”
The company is involved in various sectors at LBSP, including pharmaceuticals and medical technology. In 2023, J&J Innovative Medicine, Biologics opened a new facility on university land at Emmy Noetherweg. The latest investment in the Optima building will add more space for laboratories and offices to support production growth and innovation.
The new building will be connected to the existing structures on Einsteinweg via a bridge, creating a cohesive complex. The new facility will cover 7,000 square meters and consist of three floors.
For over three decades, the university has been working with the municipalities of Leiden and Oegstgeest to develop the Leiden Bio Science Park, with a focus on advancing public health through research and innovation in life sciences and health. While the park is primarily intended as an industrial area, the university envisions it as a growing urban district with residential areas, parks, restaurants, shops, and the Faculty of Mathematics and Natural Sciences campus. This development will continue over the coming years.
Construction of the new Johnson & Johnson facility is expected to begin in early 2026.
Image: An artist’s impression of the new building. (The final design may differ from this representation).
As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living Environment. To get to know him a bit...
Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown insulin-producing islet cells derived from...
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.